StockData
Northwest Biotherapeutics Inc logo

Northwest Biotherapeutics Inc (NWBO) stock

NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026Market cap $254.79MP/E –Yield –

Northwest Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Northwest Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $23.57M, down 31.6% year over year. For fiscal 2025 it was $28.79M, down 17.5% from the year before. Over ten years it grew -12.0% a year on average. The highest annual figure on record is $103.12M in fiscal 2015.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$28.79M-17.5%
FY2024Dec 31, 2024$34.89M+25.8%
FY2023Dec 31, 2023$27.73M-21.9%
FY2022Dec 31, 2022$35.51M+74.9%
FY2021Dec 31, 2021$20.31M-39.6%
FY2020Dec 31, 2020$33.64M+138.5%
FY2019Dec 31, 2019$14.11M-22.3%
FY2018Dec 31, 2018$18.15M-45.8%
FY2017Dec 31, 2017$33.52M-44.2%
FY2016Dec 31, 2016$60.08M-41.7%
FY2015Dec 31, 2015$103.12M+20.4%
FY2014Dec 31, 2014$85.64M+95.0%
FY2013Dec 31, 2013$43.91M+51.9%
FY2012Dec 31, 2012$28.91M+114.9%
FY2011Dec 31, 2011$13.45M+35.9%
FY2010Dec 31, 2010$9.90M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.71M-23.2%
Q1 FY2026Mar 31, 2026$4.86M-41.8%
Q4 FY2025Dec 31, 2025$5.55M-47.2%
Q3 FY2025Sep 30, 2025$7.45M-8.4%
Q2 FY2025Jun 30, 2025$7.43M-10.4%
Q1 FY2025Mar 31, 2025$8.35M+5.1%
Q4 FY2024Dec 31, 2024$10.52M+41.2%
Q3 FY2024Sep 30, 2024$8.13M+12.9%
Q2 FY2024Jun 30, 2024$8.29M+33.5%
Q1 FY2024Mar 31, 2024$7.94M+15.8%
Q4 FY2023Dec 31, 2023$7.45M-20.3%
Q3 FY2023Sep 30, 2023$7.20M-6.4%
Q2 FY2023Jun 30, 2023$6.21M-54.5%
Q1 FY2023Mar 31, 2023$6.86M+42.3%
Q4 FY2022Dec 31, 2022$9.35M+123.4%
Q3 FY2022Sep 30, 2022$7.69M+105.3%
Q2 FY2022Jun 30, 2022$13.65M+53.3%
Q1 FY2022Mar 31, 2022$4.82M-72.7%
Q4 FY2021Dec 31, 2021$4.19M+30.0%
Q3 FY2021Sep 30, 2021$3.75M-2.8%
Q4 FY2020Dec 31, 2020$8.90M+121.7%
Q3 FY2020Sep 30, 2020$17.66M+399.2%
Q2 FY2020Jun 30, 2020$3.22M-2.2%
Q1 FY2020Mar 31, 2020$3.86M+28.4%
Q4 FY2019Dec 31, 2019$4.01M+4.4%
Q3 FY2019Sep 30, 2019$3.54M-17.6%
Q2 FY2019Jun 30, 2019$3.29M-37.7%
Q1 FY2019Mar 31, 2019$3.00M-36.5%
Q4 FY2018Dec 31, 2018$3.84M-71.1%
Q3 FY2018Sep 30, 2018$4.30M-74.5%
Q2 FY2018Jun 30, 2018$5.28M-75.0%
Q1 FY2018Mar 31, 2018$4.73M-45.7%
Q4 FY2017Dec 31, 2017$13.29M-1.1%
Q4 FY2016Dec 31, 2016$16.83M-63.8%
Q3 FY2016Sep 30, 2016$21.09M–
Q2 FY2016Jun 30, 2016$8.71M–
Q1 FY2016Mar 31, 2016$13.44M–
Q4 FY2015Dec 31, 2015$46.56M–

More Northwest Biotherapeutics figures

See a number that looks wrong?